Niagen Bioscience, Inc. current report, 20 June 2008

Vollständiges Dokument

Business Context and Reporting Period

This Form 8-K, dated June 20, 2008, reports the completion of a reverse merger between Cody Resources, Inc. (a Nevada shell company) and ChromaDex, Inc. (a supplier of phytochemical reference standards). Following the transaction, Cody Resources, Inc. changed its name to ChromaDex Corporation and relocated its headquarters to Irvine, California. For accounting purposes, ChromaDex is deemed the acquirer. The filing includes audited financial statements for ChromaDex for the fiscal years ended December 29, 2007, and December 31, 2006, as well as unaudited interim statements for the three months ended March 29, 2008.

Key Financial Metrics

Revenue and Profitability (ChromaDex Historical):

  • Fiscal Year 2007 (ended Dec 29): Net Sales of $4,754,073; Net Loss of $189,875.
  • Fiscal Year 2006 (ended Dec 31): Net Sales of $3,517,957; Net Loss of $1,284,260.
  • Q1 2008 (ended March 29): Net Sales of $1,059,716; Net Loss of $122,906.

Liquidity and Capital Resources:

  • Cash Position: As of March 29, 2008, ChromaDex held $1,694,661 in cash, a significant increase from $303,785 at year-end 2007 due to a private placement.
  • Financing: Between January and May 2008, ChromaDex raised approximately $3,574,900 in a private placement, with a target of $6,000,000 total.
  • Debt: The company has capital lease obligations totaling approximately $227,337 (present value) as of December 29, 2007. A $1,002,691 promissory note was issued on June 18, 2008, to fund a share repurchase from Bayer Innovation GmbH.
  • Related Party Liabilities: As of March 29, 2008, the company owed $1,178,206 to officers in deferred compensation.

Material Changes vs. Prior Period

  • Revenue Trend: Full-year 2007 revenue increased 35% compared to 2006. However, Q1 2008 revenue decreased 12% compared to Q1 2007 due to reduced demand for analytical services and foreign reference standards.
  • Profitability Trend: The company reduced its net loss significantly in 2007 compared to 2006. However, Q1 2008 returned to a net loss of $122,906, compared to a net income of $112,993 in Q1 2007.
  • Corporate Structure: The registrant transitioned from a shell company with no operations to an operating entity focused on phytochemical standards. Former Cody management resigned, and ChromaDex management assumed control.
  • Shareholder Base: Former ChromaDex shareholders received approximately 23.5 million shares of Cody Common Stock, representing 83.94% of the post-merger company.

Guidance, Outlook, and Risks

Outlook and Strategy: Management anticipates achieving break-even in the analytical services business by mid-2008. The strategy focuses on expanding the core reference standards business (adding 500-1,000 new standards annually), expanding manufacturing capacity, and commercializing intellectual property (IP) through licensing. The company expects to meet operational requirements through the fourth quarter of 2009 based on current capital resources.

Risks and Contingencies:

  • Capital Needs: The company may require additional financing to fund R&D and growth; failure to secure this could delay operations.
  • Regulatory Environment: Operations are subject to FDA and FTC regulations regarding dietary supplements and natural products. Changes in regulations could impact demand.
  • Intellectual Property: Success depends on protecting IP through patents; there is a risk of infringement claims or failure to secure patents.
  • Stock Liquidity: The stock is subject to SEC "Penny Stock" rules and may be thinly traded. Approximately 23.5 million shares issued in the merger are restricted from public resale for one year.
  • Accounting Change: The company changed its independent auditor from Moore & Associates Chartered to McGladrey & Pullen, LLP effective June 20, 2008.

Investor Verification Checklist

  • Verify the status of the ongoing private placement offering targeting $6,000,000 and whether the full amount has been raised.
  • Confirm the timeline for the commercialization of key IP assets, specifically the Bioluminex test kit and Sclareolide/Simmondsin royalties.
  • Review the terms of the $1,002,691 promissory note issued to Bayer Innovation GmbH and the company's ability to repay it by December 20, 2008.
  • Assess the impact of the 12% revenue decline in Q1 2008 on the management's projection of achieving break-even by mid-2008.
  • Monitor the liquidity of the stock given the "Penny Stock" classification and the restriction on 83.94% of outstanding shares for one year post-merger.